Lung Cancer Genomic Testing Medicine Market

Home Healthcare And Pharmaceutical Lung Cancer Genomic Testing Medicine Market

SPECIAL OFFER : 25% Super Discount For All !

Lung Cancer Genomic Testing Medicine Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2018–2028, Segmented By Product Type (Products and Services); By Technology (Polymerase Chain Reaction, Next-Generation Sequencing, Fluorescence In-Situ Hybridization, and others); By Sample Type (Tissue Biopsy and Liquid Biopsy); By Panel Type (Multi-Gene Panel and Single-Gene Panel); By End-User (Research Organization, Hospitals/ Clinics, Diagnostic Laboratories, and others); By Region (North America, Europe, Asia Pacific, Latin America, and Middle East and Africa)

Published Date: October 2022
Report ID: BWC22465
Available Format: PDF
Page: 240

Report Overview

Global lung cancer genomic testing medicine market is growing owing to rising number of cancer patients leading to recent launches of novel lung cancer genomic testing as well as expanding research into lung cancer with an emphasis on pharmacogenomics and development of companion diagnostics.

Global Lung Cancer Genomic Testing Medicine Market - Industry Trends & Forecast Report 2028

Global lung cancer genomic testing medicine market is projected to reach USD 4.27 billion by the year 2028, exhibiting a CAGR of 10.1% during 2022-2028 (forecast period). The rapid expansion of the market is predominantly due to the rise in the number of cancer patients around the world, as well as increasing awareness and adoption of the lung cancer genomic testing medicine market, recent launches of novel lung cancer genomic testing, and expanding research in the field of lung cancer, with an emphasis on pharmacogenomics and the development of companion diagnostics is also propelling the global lung cancer genomic testing medicine market.

Global Lung Cancer Genomic Testing Medicine Market - Overview

Lung cancer genetic testing is a relatively new industry with a limited global presence. Companies are investing more money in R&D to speed up the creation of lung cancer genomic testing, which will likely lead to more people using these tests. Lung cancer genomic testing will become more widely used as healthcare systems move toward precision diagnostics and precision medicine, allowing for more educated treatment decisions and better health outcomes. As more and more international oncology societies advocate for genomic testing in lung cancer diagnosis, the worldwide lung cancer genomic testing market is poised for significant growth.

Global Lung Cancer Genomic Testing Medicine Market Forecast and Trends

Growth Drivers

The rise in the number of cancer patients driving the market growth

During the time covered by this estimate, it is anticipated that the primary factor that will be responsible for the significant rise of the market for genomic cancer testing will be the rising incidence of breast and lung cancer. The increase in the number of cancer awareness initiatives carried out by non-governmental organizations (NGOs) helps to drive the growth of the market for genomic cancer testing. The creation of innovative cancer genomic testing procedures is currently receiving a significant amount of emphasis from major manufacturers. Another important aspect that is contributing to the expansion of the market is the rising priority placed on research and development of lung cancer diagnostic and screening tests.

Restraints

Due to a lack of awareness, the market growth is restricted

The majority of people, especially those in the lower socioeconomic groups, cannot afford screening because of its high cost. It is also anticipated that there will be a reduction in the number of screening tests carried out in developing and underdeveloped nations due to a shortage of radiologists. The implementation of lung screening technologies is hampered by the aforementioned challenges, and it is projected that this will continue to be the case in the foreseeable future.

Opportunities

Evolution of healthcare systems toward precision diagnostics and precision medicinal treatments

The implementation of lung cancer genomic testing will be required as a result of the evolution of healthcare systems toward precision diagnostics and precision medicinal treatments. It can make it simpler to come to organizational decisions regarding treatment, which in turn can improve the quality of healthcare results as a whole. Many new prospects have become available on the worldwide market as a result of the growing number of recommendations made by international oncology associations about the application of genetic testing for the investigation of lung malignancies.

Impact of COVID-19 on Global Lung Cancer Genomic Testing Medicine Market

The utility of genetic testing in diagnostic laboratories, hospitals, and clinics is the primary factor driving growth in the global market for lung cancer genomic testing. At the outset of the COVID-19 pandemic, a number of countries went into full or partial lockdown, and all elective surgical procedures and treatments in healthcare settings were halted. The COVID-19 pandemic did not have an effect on the genetic testing for lung cancer because it is considered an elective procedure. As a result, the pandemic did not have an effect on lung cancer genomic testing.

Global Lung Cancer Genomic Testing Medicine Market – By Product Type

On the basis of product type, global lung cancer genomic testing medicine market is divided into products and services. The services category of the global market for lung cancer genomic testing is predicted to grow at a faster CAGR during the forecast period. This is as a result of the simple availability, accessibility, and flexibility of laboratory developed tests (LDTs), in addition to the lower cost of LDTs as compared to the market for the product that is dominated by IVDs.

Global Lung Cancer Genomic Testing Medicine Market – By Technology

On the basis of technology, global lung cancer genomic testing medicine market is divided into polymerase chain reaction, next-generation sequencing, fluorescence in-situ hybridization, and others. It is projected that polymerase chain reaction (PCR) segment will hold a dominant position in the global market for lung cancer genetic testing by 2028. This is owing to the overall cost-effectiveness and high sensitivity of the PCR-based genomic test for detecting lung cancer mutations that cause disease. The test was designed to detect mutations that cause lung cancer.

Global Lung Cancer Genomic Testing Medicine Market - By Sample Type

On the basis of sample type, global lung cancer genomic testing medicine market is divided into tissue biopsy and liquid biopsy. It is common practice in the medical industry to collect a lung tissue biopsy for the purpose of diagnosing lung cancer; this sample is then put through genomic testing. As a result, the market is expected to be dominated by sample types that are obtained through tissue biopsies.

Global Lung Cancer Genomic Testing Medicine Market - By Panel Type

On the basis of panel type, global lung cancer genomic testing medicine market is divided into multi-gene panel and single-gene panel. It is anticipated that multi-gene panels will lead the market for genomic testing in the field of lung cancer worldwide. This is because taking lung tissue biopsies for the purpose of diagnosing lung cancer is normal medical practice, and medical personnel are experienced with the process. The lung tissue biopsies that are taken can then be used for genomic testing of lung cancer.

Global Lung Cancer Genomic Testing Medicine Market - By End-User

On the basis of end-user segmentation, global lung cancer genomic testing medicine market is divided into research organization, hospitals/clinics, diagnostic laboratories and others. It is anticipated that research organizations will hold the majority of share in the global market for lung cancer genomic testing. This is because there are a significant number of clinical research and academic organizations that use lung cancer genomic testing for the development of drugs, the development of companion diagnostics, and the enrolment of patients in clinical trials.

Global Lung Cancer Genomic Testing Medicine Market – By Region

On the basis of region, the market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The market for genomic diagnostics of lung cancer will certainly be the most lucrative in North America. A large part of the credit for this goes to the numerous study, product, and service businesses that can be found in the US. The growth of the market is aided in other ways as well, including by the funding of research, the sponsorship of advancements in research, and the collaboration between prestigious institutions. The industry is also anticipated to expand in the Asia Pacific. Increased spending on life science research, technological advancements in DNA sequencing, and the emergence of new competitors are all contributing factors.

Competitive Landscape

Key players operating in the global lung cancer genomic testing medicine market are QIAGEN, Agilent Technologies Inc., Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, CENTOGENE N.V., BGI, CeGaT GmbH, Illumina Inc., F. Hoffmann-La Roche Ltd, and other prominent players. The market leaders retain their supremacy by spending quite a lot on research and development, incorporating cutting-edge technology into their goods, and releasing upgraded items for customers. Various tactics, including strategic alliances, agreements, mergers, and partnerships, are used.

Recent Development

In June of 2022, Tempus and Eli Lilly formed a partnership to provide free genomic testing for anyone with lung cancer.
In May of 2022, Roche joined forces with the Global Fund to aid developing nations in improving their access to lifesaving diagnostics.
Thermo Fisher Scientific's Oncomine Dx Target Test for EGFR Exon20 insertion mutant non-small cell lung cancer tumor tissue received FDA approval in December 2021, making it one of 12 targeted therapies for NSCLC to receive this stamp of approval around the world.
Thermo Fisher Scientific's Oncomine Dx Target Test, a tissue-based NGS companion diagnostic, was approved by the FDA as CDx for five targeted NSCLC therapies in the US in September 2021. This approval was for Takeda's targeted therapy for NSCLC patients with EGFR Exon20 insertion mutations.
Qiagen introduced the first tissue companion diagnostic approved by the FDA in May 2021 to detect the KRAS G12C mutation in NSCLC tumors, hence increasing the availability of precision medicine treatment choices for lung cancer patients.

Scope of the Report

Attributes	Details
Years Considered	Historical data – 2018–2021
	Base Year – 2021
	Estimated Year – 2022
	Forecast – 2022–2028
Facts Covered	Revenue in USD Billion
Market Coverage	North America, Europe, Asia Pacific, Latin America, and Middle East and Africa
Product Service/Segmentation	By Product Type, By Technology, By Sample Type, By Panel Type, By End-User, By Region
Key Players	QIAGEN, Agilent Technologies Inc., Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, CENTOGENE N.V., BGI, CeGaT GmbH, Illumina Inc., F. Hoffmann-La Roche Ltd, and other prominent players.

By Product Type

Products
Services

By Technology

Polymerase Chain Reaction
Next-Generation Sequencing
Fluorescence In-Situ Hybridization
Others

By Sample Type

Tissue Biopsy
Liquid Biopsy

By Panel Type

Multi-Gene Panel
Single-Gene Panel

By End-User

Research Organization
Hospitals/Clinics
Diagnostic Laboratories
Others

By Region

North America
Europe
Asia Pacific
Latin America
Middle East and Africa

Research Framework
1. Research Objective
2. Product Type Overview
3. Market Segmentation
Executive Summary
Global Lung Cancer Genomic Testing Medicine Market Insights
1. Industry Value Chain Analysis
2. DROC Analysis
  1. Growth Drivers
  2. Restraints
  3. Opportunity
  4. Challenges
3. Technological Advancement/Recent Development
4. Regulatory Framework
5. Porter’s Five Forces Analysis
  1. Bargaining Power of Suppliers
  2. Bargaining Power of Buyers
  3. Threat of New Entrants
  4. Threat of Substitutes
  5. Intensity of Rivalry
Global Lung Cancer Genomic Testing Medicine Market Overview
1. Market Size & Forecast by Value, 2018-2028
  1. By Value (USD Billion)
2. Market Share & Forecast
  1. By Product Type
    1. Products
    2. Services
  2. By Technology
    1. Polymerase Chain Reaction
    2. Next-Generation Sequencing
    3. Fluorescence In-Situ Hybridization
    4. Others
  3. By Sample Type
    1. Tissue Biopsy
    2. Liquid Biopsy
  4. By Panel Type
    1. Multi-Gene Panel
    2. Single-Gene Panel
  5. By End-User
    1. Research Organization
    2. Hospitals/Clinics
    3. Diagnostic Laboratories
    4. Others
  6. By Region
    1. North America
    2. Europe
    3. Asia Pacific
    4. Latin America
    5. Middle East and Africa
North America Lung Cancer Genomic Testing Medicine Market
1. 1. Market Size & Forecast by Value, 2018-2028
  2. By Value (USD Billion)
2. Market Share & Forecast
  1. By Product Type
  2. By Technology
  3. By Sample Type
  4. By Panel Type
  5. By End-User
  6. By Country
    1. US
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    2. Canada
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
Europe Lung Cancer Genomic Testing Medicine Market
1. Market Size & Forecast by Value, 2018-2028
  1. By Value (USD Billion)
2. Market Share & Forecast
  1. By Product Type
  2. By Technology
  3. By Sample Type
  4. By Panel Type
  5. By End-User
  6. By Country
    1. Germany
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    2. UK
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    3. Italy
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    4. France
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    5. Spain
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    6. The Netherlands
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    7. NORDIC Countries
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    8. Rest of Europe
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
Asia Pacific Lung Cancer Genomic Testing Medicine Market
1. Market Size & Forecast by Value, 2018-2028
  1. By Value (USD Billion)
2. Market Share & Forecast
  1. By Product Type
  2. By Technology
  3. By Sample Type
  4. By Panel Type
  5. By End-User
  6. By Country
    1. China
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    2. India
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    3. Japan
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    4. South Korea
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    5. Australia & New Zealand
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    6. Indonesia
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    7. Malaysia
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    8. Singapore
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    9. Philippines
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    10. Vietnam
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    11. Rest of Asia Pacific
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
Latin America Lung Cancer Genomic Testing Medicine Market
1. Market Size & Forecast by Value, 2018-2028
  1. By Value (USD Billion)
2. Market Share & Forecast
  1. By Product Type
  2. By Technology
  3. By Sample Type
  4. By Panel Type
  5. By End-User
  6. By Country
    1. Brazil
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    2. Mexico
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    3. Argentina
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    4. Peru
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    5. Colombia
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    6. Rest of Latin America
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
Middle East & Africa Lung Cancer Genomic Testing Medicine Market
1. Market Size & Forecast by Value, 2018-2028
  1. By Value (USD Billion)
2. Market Share & Forecast
  1. By Product Type
  2. By Technology
  3. By Sample Type
  4. By Panel Type
  5. By End-User
  6. By Country
    1. Saudi Arabia
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    2. UAE
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    3. Qatar
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    4. Kuwait
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    5. Iran
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    6. South Africa
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    7. Nigeria
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    8. Kenya
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    9. Egypt
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    10. Morocco
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    11. Algeria
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
    12. Rest of Middle East & Africa
      1. By Product Type
      2. By Technology
      3. By Sample Type
      4. By Panel Type
      5. By End-User
Competitive Landscape
1. List of Key Players and Their Offerings
2. Global Lung Cancer Genomic Testing Medicine Company Market Share Analysis, 2021
3. Competitive Benchmarking, By Operating Parameters
4. Key Strategic Development (Merger, Acquisition, Partnership, and others)
Impact of Covid-19 on Global Lung Cancer Genomic Testing Medicine System Market
Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook)
1. QIAGEN
2. Agilent Technologies, Inc.
3. Thermo Fisher Scientific Inc.
4. Quest Diagnostics Incorporated.
5. Laboratory Corporation of America Holdings.
6. CENTOGENE N.V.
7. BGI
8. CeGaT GmbH
9. Illumina, Inc.
10. F. Hoffmann-La Roche Ltd
11. Others
Key Strategic Recommendations
Research Methodology
1. Qualitative Research
  1. Primary & Secondary Research
2. Quantitative Research
3. Market Breakdown & Data Triangulation
  1. Secondary Research
  2. Primary Research
4. Breakdown of Primary Research Respondents, By Region
5. Assumption & Limitation

*Financial information in case of non-listed companies will be provided as per availability

**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable

List Of Figures

Figure 1 Global Lung Cancer Genomic Testing Medicine Market Segmentation

Figure 2 Global Lung Cancer Genomic Testing Medicine Market Value Chain Analysis

Figure 3 Company Market Share Analysis, 2021

Figure 4 Global Lung Cancer Genomic Testing Medicine Market Size, By Value (USD Million), 2018-2028

Figure 5 Global Lung Cancer Genomic Testing Medicine Market Share, By Product Type, By Value, 2018-2028

Figure 6 Global Lung Cancer Genomic Testing Medicine Market Share, By Technology, By Value, 2018-2028

Figure 7 Global Lung Cancer Genomic Testing Medicine Market Share, By Sample Type, By Value, 2018-2028

Figure 8 Global Lung Cancer Genomic Testing Medicine Market Share, By Panel Type, By Value, 2018-2028

Figure 9 Global Lung Cancer Genomic Testing Medicine Market Share, By End User, By Value, 2018-2028

Figure 10 Global Lung Cancer Genomic Testing Medicine Market Share, By Region, By Value, 2018-2028

Figure 11 North America Lung Cancer Genomic Testing Medicine Market Size, By Value (USD Million), 2018-2028

Figure 12 North America Lung Cancer Genomic Testing Medicine Market Share, By Product Type, By Value, 2018-2028

Figure 13 North America Lung Cancer Genomic Testing Medicine Market Share, By Technology, By Value, 2018-2028

Figure 14 North America Lung Cancer Genomic Testing Medicine Market Share, By Sample Type, By Value, 2018-2028

Figure 15 North America Lung Cancer Genomic Testing Medicine Market Share, By Panel Type, By Value, 2018-2028

Figure 16 North America Lung Cancer Genomic Testing Medicine Market Share, By End User, By Value, 2018-2028

Figure 17 North America Lung Cancer Genomic Testing Medicine Market Share, By Country, By Value, 2018-2028

Figure 18 US Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 19 US Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 20 US Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 21 US Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 22 US Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 23 US Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 24 Canada Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 25 Canada Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 26 Canada Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 27 Canada Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 28 Canada Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 28 Canada Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 30 Europe Lung Cancer Genomic Testing Medicine Market Size, By Value (USD Million), 2018-2028

Figure 31 Europe Lung Cancer Genomic Testing Medicine Market Share, By Product Type, By Value, 2018-2028

Figure 32 Europe Lung Cancer Genomic Testing Medicine Market Share, By Technology, By Value, 2018-2028

Figure 33 Europe Lung Cancer Genomic Testing Medicine Market Share, By Sample Type, By Value, 2018-2028

Figure 34 Europe Lung Cancer Genomic Testing Medicine Market Share, By Panel Type, By Value, 2018-2028

Figure 35 Europe Lung Cancer Genomic Testing Medicine Market Share, By End User, By Value, 2018-2028

Figure 36 Europe Lung Cancer Genomic Testing Medicine Market Share, By Country, By Value, 2018-2028

Figure 37 Germany Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 38 Germany Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 39 Germany Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 40 Germanys Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 41 Germany Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 42 Germany Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 43 UK Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 44 UK Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 45 UK Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 46 UK Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 47 UK Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 48 UK Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 49 Italy Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 50 Italy Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 51 Italy Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 52 Italy Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 53 Italy Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 54 Italy Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 55 France Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 56 France Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 57 France Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 58 France Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 59 France Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 60 France Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 61 Spain Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 62 Spain Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 63 Spain Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 64 Spain Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 65 Spain Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 66 Spain Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 67 The Netherlands Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 68 The Netherlands Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 69 The Netherlands Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 70 The Netherlands Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 71 The Netherlands Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 72 The Netherlands Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 73 NORDIC Countries Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 74 NORDIC Countries Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 75 NORDIC Countries Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 76 NORDIC Countries Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 77 NORDIC Countries Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 78 NORDIC Countries Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 79 Rest of Europe Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 80 Rest of Europe Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 81 Rest of Europe Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 82 Rest of Europe Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 83 Rest of Europe Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 84 Rest of Europe Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 85 The Asia-Pacific Lung Cancer Genomic Testing Medicine Market Size, By Value (USD Million), 2018-2028

Figure 86 The Asia-Pacific Lung Cancer Genomic Testing Medicine Market Share, By Product Type, By Value, 2018-2028

Figure 87 The Asia-Pacific Lung Cancer Genomic Testing Medicine Market Share, By Technology, By Value, 2018-2028

Figure 88 The Asia-Pacific Lung Cancer Genomic Testing Medicine Market Share, By Sample Type, By Value, 2018-2028

Figure 89 The Asia-Pacific Lung Cancer Genomic Testing Medicine Market Share, By Panel Type, By Value, 2018-2028

Figure 90 The Asia-Pacific Lung Cancer Genomic Testing Medicine Market Share, By End User, By Value, 2018-2028

Figure 91 The Asia-Pacific Lung Cancer Genomic Testing Medicine Market Share, By Country, By Value, 2018-2028

Figure 92 China Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 93 China Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 94 China Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 95 China Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 96 China Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 97 China Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 98 India Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 99 India Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 100 India Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 101 India Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 102 India Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 103 India Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 104 Japan Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 105 Japan Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 106 Japan Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 107 Japan Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 108 Japan Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 109 Japan Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 110 South Korea Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 111 South Korea Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 112 South Korea Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 113 South Korea Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 114 South Korea Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 115 South Korea Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 116 Australia & New Zealand Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 117 Australia & New Zealand Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 118 Australia & New Zealand Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 119 Australia & New Zealand Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 120 Australia & New Zealand Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 121 Australia & New Zealand Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 122 Indonesia Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 123 Indonesia Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 124 Indonesia Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 125 Indonesia Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 126 Indonesia Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 127 Indonesia Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 128 Malaysia Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 129 Malaysia Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 130 Malaysia Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 131 Malaysia Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 132 Malaysia Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 133 Malaysia Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 134 Singapore Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 135 Singapore Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 136 Singapore Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 137 Singapore Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 138 Singapore Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 139 Singapore Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 140 Philippines Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 141 Philippines Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 142 Philippines Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 143 Philippines Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 144 Philippines Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 145 Philippines Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 146 Vietnam Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 147 Vietnam Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 148 Vietnam Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 149 Vietnam Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 150 Vietnam Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 151 Vietnam Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 152 Latin America Lung Cancer Genomic Testing Medicine Market Size, By Value (USD Million), 2018-2028

Figure 153 Latin America Lung Cancer Genomic Testing Medicine Market Share, By Product Type, By Value, 2018-2028

Figure 154 Latin America Lung Cancer Genomic Testing Medicine Market Share, By Technology, By Value, 2018-2028

Figure 155 Latin America Lung Cancer Genomic Testing Medicine Market Share, By Sample Type, By Value, 2018-2028

Figure 156 Latin America Lung Cancer Genomic Testing Medicine Market Share, By Panel Type, By Value, 2018-2028

Figure 157 Latin America Lung Cancer Genomic Testing Medicine Market Share, By End User, By Value, 2018-2028

Figure 158 Latin America Lung Cancer Genomic Testing Medicine Market Share, By Country, By Value, 2018-2028

Figure 159 Brazil Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 160 Brazil Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 161 Brazil Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 162 Brazil Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 163 Brazil Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 164 Brazil Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 165 Mexico Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 166 Mexico Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 167 Mexico Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 168 Mexico Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 169 Mexico Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 170 Mexico Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 171 Argentina Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 172 Argentina Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 173 Argentina Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 174 Argentina Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 175 Argentina Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 176 Argentina Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 177 Peru Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 178 Peru Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 179 Peru Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 180 Peru Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 181 Peru Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 182 Peru Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 183 Colombia Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 184 Colombia Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 185 Colombia Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 186 Colombia Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 187 Colombia Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 188 Colombia Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 189 Rest of Latin America Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 190 Rest of Latin America Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 191 Rest of Latin America Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 192 Rest of Latin America Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 193 Rest of Latin America Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 194 Rest of Latin America Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 195 The Middle East & Africa Lung Cancer Genomic Testing Medicine Market Size, By Value (USD Million), 2018-2028

Figure 196 The Middle East & Africa Lung Cancer Genomic Testing Medicine Market Share, By Product Type, By Value, 2018-2028

Figure 197 The Middle East & Africa Lung Cancer Genomic Testing Medicine Market Share, By Technology, By Value, 2018-2028

Figure 198 The Middle East & Africa Lung Cancer Genomic Testing Medicine Market Share, By Sample Type, By Value, 2018-2028

Figure 199 The Middle East & Africa Lung Cancer Genomic Testing Medicine Market Share, By Panel Type, By Value, 2018-2028

Figure 200 The Middle East & Africa Lung Cancer Genomic Testing Medicine Market Share, By End User, By Value, 2018-2028

Figure 201 The Middle East & Africa Lung Cancer Genomic Testing Medicine Market Share, By Country, By Value, 2018-2028

Figure 202 Saudi Arabia Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 203 Saudi Arabia Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 204 Saudi Arabia Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 205 Saudi Arabia Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 206 Saudi Arabia Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 207 Saudi Arabia Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 208 UAE Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 209 UAE Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 210 UAE Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 211 UAE Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 212 UAE Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 213 UAE Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 214 Qatar Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 215 Qatar Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 216 Qatar Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 217 Qatar Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 218 Qatar Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 219 Qatar Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 220 Kuwait Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 221 Kuwait Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 222 Kuwait Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 223 Kuwait Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 224 Kuwait Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 225 Kuwait Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 226 Iran Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 227 Iran Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 228 Iran Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 229 Iran Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 230 Iran Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 231 Iran Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 232 South Africa Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 233 South Africa Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 234 South Africa Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 235 South Africa Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 236 South Africa Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 237 South Africa Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 238 Nigeria Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 239 Nigeria Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 240 Nigeria Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 241 Nigeria Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 242 Nigeria Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 243 Nigeria Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 244 Kenya Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 245 Kenya Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 246 Kenya Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 247 Kenya Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 248 Kenya Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 249 Kenya Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 250 Egypt Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 251 Egypt Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 252 Egypt Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 253 Egypt Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 254 Egypt Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 255 Egypt Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 266 Morocco Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 267 Morocco Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 268 Morocco Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 269 Morocco Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 270 Morocco Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 271 Morocco Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 272 Algeria Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 273 Algeria Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 274 Algeria Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 275 Algeria Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 276 Algeria Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 277 Algeria Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

Figure 278 Rest of Middle East & Africa Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Figure 279 Rest of Middle East & Africa Minimal Residual Disease (MRD) Testing Market Share, By Product Type, By Value, 2018-2028

Figure 280 Rest of Middle East & Africa Minimal Residual Disease (MRD) Testing Market Share, By Technology, By Value, 2018-2028

Figure 281 Rest of Middle East & Africa Minimal Residual Disease (MRD) Testing Market Share, By Sample Type, By Value, 2018-2028

Figure 282 Rest of Middle East & Africa Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By Value, 2018-2028

Figure 283 Rest of Middle East & Africa Minimal Residual Disease (MRD) Testing Market Share, By End User, By Value, 2018-2028

List Of Tables

Table 1 Global Lung Cancer Genomic Testing Medicine Market Size, By Product Type, By

Value, 2018-2028

Table 2 Global Lung Cancer Genomic Testing Medicine Market Size, By

Technology, By Value, 2018-2028

Table 3 Global Lung Cancer Genomic Testing Medicine Market Size, By Sample,

By Value, 2018-2028

Table 4 Global Lung Cancer Genomic Testing Medicine Market Size, By Panel,

By Value, 2018-2028

Table 5 Global Lung Cancer Genomic Testing Medicine Market Size, By End User, By

Value, 2018-2028

Table 6 Global Lung Cancer Genomic Testing Medicine Market Size, By Region, By

Value, 2018-2028

Table 7 North America Lung Cancer Genomic Testing Medicine Market Size, By Product

Type, By Value, 2018-2028

Table 8 North America Lung Cancer Genomic Testing Medicine Market Size, By

Technology, By Value, 2018-2028

Table 9 North America Lung Cancer Genomic Testing Medicine Market Size, By

Sample Type, By Value, 2018-2028

Table 10 North America Lung Cancer Genomic Testing Medicine Market Size, By

Panel Type, By Value, 2018-2028

Table 11 North America Lung Cancer Genomic Testing Medicine Market Size, By End User,

By Value, 2018-2028

Table 12 North America Lung Cancer Genomic Testing Medicine Market Size, By Country,

By Value, 2018-2028

Table 13 US Minimal Residual Disease (MRD) Testing Market Size, By Value

(USD Million), 2018-2028

Table 14 US Minimal Residual Disease (MRD) Testing Market Size, By Product

Type, By Value, 2018-2028

Table 15 US Minimal Residual Disease (MRD) Testing Market Size, By

Technology, By Value, 2018-2028

Table 16 US Minimal Residual Disease (MRD) Testing Market Size, By Sample

Type, By Value, 2018-2028

Table 17 US Minimal Residual Disease (MRD) Testing Market Size, By Panel

Type, By Value, 2018-2028

Table 18 US Minimal Residual Disease (MRD) Testing Market Size, By End User,

By Value, 2018-2028

Table 19 Canada Minimal Residual Disease (MRD) Testing Market Size, By Value (USD

Million), 2018-2028

Table 20 Canada Minimal Residual Disease (MRD) Testing Market Share, By Product Type,

By Value, 2018-2028

Table 21 Canada Minimal Residual Disease (MRD) Testing Market Share, By Technology, By

Value, 2018-2028

Table 22 Canada Minimal Residual Disease (MRD) Testing Market Share, By Sample Type,

By Value, 2018-2028

Table 23 Canada Minimal Residual Disease (MRD) Testing Market Share, By Panel Type, By

Value, 2018-2028

Table 24 Canada Minimal Residual Disease (MRD) Testing Market Share, By End User, By

Value, 2018-2028

Table 25 Europe Lung Cancer Genomic Testing Medicine Market Size, By Product Type,

By Value, 2018-2028

Table 26 Europe Lung Cancer Genomic Testing Medicine Market Size, By Technology, By

Value, 2018-2028

Table 27 Europe Lung Cancer Genomic Testing Medicine Market Size, By Sample Type, By

Value, 2018-2028

Table 28 Europe Lung Cancer Genomic Testing Medicine Market Size, By Panel Type, By

Value, 2018-2028

Table 29 Europe Lung Cancer Genomic Testing Medicine Market Size, By End User, By

Value, 2018-2028

Table 30 Europe Lung Cancer Genomic Testing Medicine Market Size, By Country, By Value,

2018-2028

Table 31 Germany Minimal Residual Disease (MRD) Testing Market Size, By Value (USD

Million), 2018-2028

Table 32 Germany Minimal Residual Disease (MRD) Testing Market Size, By Product Type,

By Value, 2018-2028

Table 33 Germany Minimal Residual Disease (MRD) Testing Market Size, By Technology, By

Value, 2018-2028

Table 34 Germanys Minimal Residual Disease (MRD) Testing Market Size, By Sample Type,

By Value, 2018-2028

Table 35 Germany Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By

Value, 2018-2028

Table 36 Germany Minimal Residual Disease (MRD) Testing Market Size, By End User, By

Value, 2018-2028

Table 37 UK Minimal Residual Disease (MRD) Testing Market Size, By Value

(USD Million), 2018-2028

Table 38 UK Minimal Residual Disease (MRD) Testing Market Size, By Product

Type, By Value, 2018-2028

Table 39 UK Minimal Residual Disease (MRD) Testing Market Size, By

Technology, By Value, 2018-2028

Table 40 UK Minimal Residual Disease (MRD) Testing Market Size, By Sample

Type, By Value, 2018-2028

Table 41 UK Minimal Residual Disease (MRD) Testing Market Size, By Panel

Type, By Value, 2018-2028

Table 42 UK Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 43 Italy Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million),

2018-2028

Table 44 Italy Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By

Value, 2018-2028

Table 45 Italy Minimal Residual Disease (MRD) Testing Market Size, By Technology, By

Value, 2018-2028

Table 46 Italy Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By

Value, 2018-2028

Table 47 Italy Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By

Value, 2018-2028

Table 48 Italy Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value,

2018-2028

Table 49 France Minimal Residual Disease (MRD) Testing Market Size, By Value (USD

Million), 2018-2028

Table 50 France Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By

Value, 2018-2028

Table 51 France Minimal Residual Disease (MRD) Testing Market Size, By Technology, By

Value, 2018-2028

Table 52 France Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By

Value, 2018-2028

Table 53 France Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By

Value, 2018-2028

Table 54 France Minimal Residual Disease (MRD) Testing Market Size, By End User, By

Value, 2018-2028

Table 55 Spain Minimal Residual Disease (MRD) Testing Market Size, By Value (USD

Million), 2018-2028

Table 56 Spain Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By

Value, 2018-2028

Table 57 Spain Minimal Residual Disease (MRD) Testing Market Size, By Technology, By

Value, 2018-2028

Table 58 Spain Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By

Value, 2018-2028

Table 59 Spain Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By

Value, 2018-2028

Table 60 Spain Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value,

2018-2028

Table 61 The Netherlands Minimal Residual Disease (MRD) Testing Market Size, By Value

(USD Million), 2018-2028

Table 62 The Netherlands Minimal Residual Disease (MRD) Testing Market Size, By Product

Type, By Value, 2018-2028

Table 63 The Netherlands Minimal Residual Disease (MRD) Testing Market Size, By

Technology, By Value, 2018-2028

Table 64 The Netherlands Minimal Residual Disease (MRD) Testing Market Size, By Sample

Type, By Value, 2018-2028

Table 65 The Netherlands Minimal Residual Disease (MRD) Testing Market Size, By Panel

Type, By Value, 2018-2028

Table 66 The Netherlands Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 67 NORDIC Countries Minimal Residual Disease (MRD) Testing Market Size, By Value

(USD Million), 2018-2028

Table 68 NORDIC Countries Minimal Residual Disease (MRD) Testing Market Size, By

Product Type, By Value, 2018-2028

Table 69 NORDIC Countries Minimal Residual Disease (MRD) Testing Market Size, By

Technology, By Value, 2018-2028

Table 70 NORDIC Countries Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 71 NORDIC Countries Minimal Residual Disease (MRD) Testing Market Size, By Panel

Type, By Value, 2018-2028

Table 72 NORDIC Countries Minimal Residual Disease (MRD) Testing Market Size, By End

User, By Value, 2018-2028

Table 73 Rest of Europe Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 74 Rest of Europe Minimal Residual Disease (MRD) Testing Market Size, By Product

Type, By Value, 2018-2028

Table 75 Rest of Europe Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 76 Rest of Europe Minimal Residual Disease (MRD) Testing Market Size, By Sample

Type, By Value, 2018-2028

Table 77 Rest of Europe Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 78 Rest of Europe Minimal Residual Disease (MRD) Testing Market Size, By End User,

By Value, 2018-2028

Table 79 The Asia-Pacific Lung Cancer Genomic Testing Medicine Market Size, By Product

Type, By Value, 2018-2028

Table 80 The Asia-Pacific Lung Cancer Genomic Testing Medicine Market Size, By

Technology, By Value, 2018-2028

Table 81 The Asia-Pacific Lung Cancer Genomic Testing Medicine Market Size, By Sample

Type, By Value, 2018-2028

Table 82 The Asia-Pacific Lung Cancer Genomic Testing Medicine Market Size, By Panel

Type, By Value, 2018-2028

Table 83 The Asia-Pacific Lung Cancer Genomic Testing Medicine Market Size, By End User,

By Value, 2018-2028

Table 84 The Asia-Pacific Lung Cancer Genomic Testing Medicine Market Size, By Country,

By Value, 2018-2028

Table 85 China Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 86 China Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By

Value, 2018-2028

Table 87 China Minimal Residual Disease (MRD) Testing Market Size, By Technology, By

Value, 2018-2028

Table 88 China Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By

Value, 2018-2028

Table 89 China Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By

Value, 2018-2028

Table 90 China Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 91 India Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 92 India Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By

Value, 2018-2028

Table 93 India Minimal Residual Disease (MRD) Testing Market Size, By Technology, By

Value, 2018-2028

Table 94 India Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By

Value, 2018-2028

Table 95 India Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By

Value, 2018-2028

Table 96 India Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value,

2018-2028

Table 97 Japan Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 98 Japan Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By

Value, 2018-2028

Table 99 Japan Minimal Residual Disease (MRD) Testing Market Size, By Technology, By

Value, 2018-2028

Table 100 Japan Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By

Value, 2018-2028

Table 101 Japan Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By

Value, 2018-2028

Table 102 Japan Minimal Residual Disease (MRD) Testing Market Size, By End User, By

Value, 2018-2028

Table 103 South Korea Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 104 South Korea Minimal Residual Disease (MRD) Testing Market Size, By Product

Type, By Value, 2018-2028

Table 105 South Korea Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 106 South Korea Minimal Residual Disease (MRD) Testing Market Size, By Sample

Type, By Value, 2018-2028

Table 107 South Korea Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 108 South Korea Minimal Residual Disease (MRD) Testing Market Size, By End User,

By Value, 2018-2028

Table 109 Australia & New Zealand Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 110 Australia & New Zealand Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 111 Australia & New Zealand Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 112 Australia & New Zealand Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 113 Australia & New Zealand Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 114 Australia & New Zealand Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 115 Indonesia Minimal Residual Disease (MRD) Testing Market Size, By Value (USD

Million), 2018-2028

Table 116 Indonesia Minimal Residual Disease (MRD) Testing Market Size, By Product Type,

By Value, 2018-2028

Table 117 Indonesia Minimal Residual Disease (MRD) Testing Market Size, By Technology,

By Value, 2018-2028

Table 118 Indonesia Minimal Residual Disease (MRD) Testing Market Size, By Sample Type,

By Value, 2018-2028

Table 119 Indonesia Minimal Residual Disease (MRD) Testing Market Size, By Panel Type,

By Value, 2018-2028

Table 120 Indonesia Minimal Residual Disease (MRD) Testing Market Size, By End User, By

Value, 2018-2028

Table 121 Malaysia Minimal Residual Disease (MRD) Testing Market Size, By Value (USD

Million), 2018-2028

Table 122 Malaysia Minimal Residual Disease (MRD) Testing Market Size, By Product Type,

By Value, 2018-2028

Table 123 Malaysia Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 124 Malaysia Minimal Residual Disease (MRD) Testing Market Size, By Sample Type,

By Value, 2018-2028

Table 125 Malaysia Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By

Value, 2018-2028

Table 126 Malaysia Minimal Residual Disease (MRD) Testing Market Size, By End User, By

Value, 2018-2028

Table 127 Singapore Minimal Residual Disease (MRD) Testing Market Size, By Value (USD

Million), 2018-2028

Table 128 Singapore Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 129 Singapore Minimal Residual Disease (MRD) Testing Market Size, By Technology,

By Value, 2018-2028

Table 130 Singapore Minimal Residual Disease (MRD) Testing Market Size, By Sample Type,

By Value, 2018-2028

Table 131 Singapore Minimal Residual Disease (MRD) Testing Market Size, By Panel Type,

By Value, 2018-2028

Table 132 Singapore Minimal Residual Disease (MRD) Testing Market Size, By End User, By

Value, 2018-2028

Table 133 Philippines Minimal Residual Disease (MRD) Testing Market Size, By Value (USD

Million), 2018-2028

Table 134 Philippines Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 135 Philippines Minimal Residual Disease (MRD) Testing Market Size, By Technology,

By Value, 2018-2028

Table 136 Philippines Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 137 Philippines Minimal Residual Disease (MRD) Testing Market Size, By Panel Type,

By Value, 2018-2028

Table 138 Philippines Minimal Residual Disease (MRD) Testing Market Size, By End User, By

Value, 2018-2028

Table 139 Vietnam Minimal Residual Disease (MRD) Testing Market Size, By Value (USD

Million), 2018-2028

Table 140 Vietnam Minimal Residual Disease (MRD) Testing Market Size, By Product Type,

By Value, 2018-2028

Table 141 Vietnam Minimal Residual Disease (MRD) Testing Market Size, By Technology, By

Value, 2018-2028

Table 142 Vietnam Minimal Residual Disease (MRD) Testing Market Size, By Sample Type,

By Value, 2018-2028

Table 143 Vietnam Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By

Value, 2018-2028

Table 144 Vietnam Minimal Residual Disease (MRD) Testing Market Size, By End User, By

Value, 2018-2028

Table 145 Latin America Lung Cancer Genomic Testing Medicine Market Size, By Product

Type, By Value, 2018-2028

Table 146 Latin America Lung Cancer Genomic Testing Medicine Market Size, By

Technology, By Value, 2018-2028

Table 147 Latin America Lung Cancer Genomic Testing Medicine Market Size, By Sample

Type, By Value, 2018-2028

Table 148 Latin America Lung Cancer Genomic Testing Medicine Market Size, By Panel

Type, By Value, 2018-2028

Table 149 Latin America Lung Cancer Genomic Testing Medicine Market Size, By End User,

By Value, 2018-2028

Table 149 Latin America Lung Cancer Genomic Testing Medicine Market Size, By

Country, By Value, 2018-2028

Table 150 Brazil Minimal Residual Disease (MRD) Testing Market Size, By Value (USD

Million), 2018-2028

Table 151 Brazil Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By

Value, 2018-2028

Table 152 Brazil Minimal Residual Disease (MRD) Testing Market Size, By Technology, By

Value, 2018-2028

Table 153 Brazil Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 154 Brazil Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 155 Brazil Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 156 Mexico Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 157 Mexico Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 158 Mexico Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 159 Mexico Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 160 Mexico Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 161 Mexico Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 162 Argentina Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 163 Argentina Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 164 Argentina Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 165 Argentina Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 166 Argentina Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 167 Argentina Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 168 Peru Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 169 Peru Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 170 Peru Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 171 Peru Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 172 Peru Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 173 Peru Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 174 Colombia Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 175 Colombia Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 176 Colombia Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 177 Colombia Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 178 Colombia Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 179 Colombia Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 180 Rest of Latin America Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 181 Rest of Latin America Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 182 Rest of Latin America Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 183 Rest of Latin America Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 184 Rest of Latin America Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 185 Rest of Latin America Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 186 The Middle East & Africa Lung Cancer Genomic Testing Medicine Market Size, By Product Type, By Value, 2018-2028

Table 187 The Middle East & Africa Lung Cancer Genomic Testing Medicine Market Size, By Technology, By Value, 2018-2028

Table 188 The Middle East & Africa Lung Cancer Genomic Testing Medicine Market Size, By Sample Type, By Value, 2018-2028

Table 189 The Middle East & Africa Lung Cancer Genomic Testing Medicine Market Size, By Panel Type, By Value, 2018-2028

Table 190 The Middle East & Africa Lung Cancer Genomic Testing Medicine Market Size, By End User, By Value, 2018-2028

Table 191 The Middle East & Africa Lung Cancer Genomic Testing Medicine Market Size, By Country, By Value, 2018-2028

Table 192 Saudi Arabia Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 193 Saudi Arabia Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 194 Saudi Arabia Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 195 Saudi Arabia Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 196 Saudi Arabia Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 197 Saudi Arabia Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 198 UAE Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 199 UAE Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 200 UAE Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 201 UAE Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 202 UAE Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 203 UAE Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 204 Qatar Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 205 Qatar Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 206 Qatar Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 207 Qatar Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 208 Qatar Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 209 Qatar Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 210 Kuwait Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 211 Kuwait Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 212 Kuwait Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 213 Kuwait Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 214 Kuwait Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 215 Kuwait Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 216 Iran Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 217 Iran Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 218 Iran Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 219 Iran Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 220 Iran Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 221 Iran Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 222 South Africa Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 223 South Africa Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 224 South Africa Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 225 South Africa Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 226 South Africa Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 227 South Africa Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 228 Nigeria Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 229 Nigeria Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 230 Nigeria Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 231 Nigeria Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 232 Nigeria Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 233 Nigeria Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 234 Kenya Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 235 Kenya Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 236 Kenya Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 237 Kenya Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 238 Kenya Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 239 Kenya Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 240 Egypt Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 241 Egypt Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 242 Egypt Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 243 Egypt Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 244 Egypt Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 245 Egypt Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 246 Morocco Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 247 Morocco Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 248 Morocco Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 249 Morocco Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 250 Morocco Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 251 Morocco Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 252 Algeria Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 253 Algeria Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 254 Algeria Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 255 Algeria Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 256 Algeria Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 257 Algeria Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 258 Rest of Middle East & Africa Minimal Residual Disease (MRD) Testing Market Size, By Value (USD Million), 2018-2028

Table 259 Rest of Middle East & Africa Minimal Residual Disease (MRD) Testing Market Size, By Product Type, By Value, 2018-2028

Table 260 Rest of Middle East & Africa Minimal Residual Disease (MRD) Testing Market Size, By Technology, By Value, 2018-2028

Table 261 Rest of Middle East & Africa Minimal Residual Disease (MRD) Testing Market Size, By Sample Type, By Value, 2018-2028

Table 262 Rest of Middle East & Africa Minimal Residual Disease (MRD) Testing Market Size, By Panel Type, By Value, 2018-2028

Table 263 Rest of Middle East & Africa Minimal Residual Disease (MRD) Testing Market Size, By End User, By Value, 2018-2028

Table 264 QIAGEN Company Overview

Table 265 QIAGEN Financial Overview

Table 266 AGILENT TECHNOLOGIES, INC. Company Overview

Table 267 AGILENT TECHNOLOGIES, INC. Financial Overview

Table 268 Thermo Fisher Scientific Inc. Company Overview

Table 269 Thermo Fisher Scientific Inc. Financial Overview

Table 270 QUEST DIAGNOSTICS INCORPORATED. Company Overview

Table 271 QUEST DIAGNOSTICS INCORPORATED. Financial Overview

Table 272 Laboratory Corporation of America Holdings. Company Overview

Table 273 Laboratory Corporation of America Holdings. Financial Overview

Table 274 CENTOGENE N.V. Company Overview

Table 275 CENTOGENE N.V. Financial Overview

Table 276 BGI Company Overview

Table 277 BGI Financial Overview

Table 278 CeGaT GmbH Company Overview

Table 279 CeGaT GmbH Financial Overview

Table 280 Illumina, Inc. Company Overview

Table 281 Illumina, Inc. Financial Overview

Table 282 F. HOFFMANN-LA ROCHE LTD Company Overview

Table 283 F. HOFFMANN-LA ROCHE LTD Financial Overview

Market Segmentation

By Product Type

Products
Services

By Technology

Polymerase Chain Reaction
Next-Generation Sequencing
Fluorescence In-Situ Hybridization
Others

By Sample Type

Tissue Biopsy
Liquid Biopsy

By Panel Type

Multi-Gene Panel
Single-Gene Panel

By End-User

Research Organization
Hospitals/Clinics
Diagnostic Laboratories
Others

By Region

North America
Europe
Asia Pacific
Latin America
Middle East and Africa

No data available

To request a free sample copy of this report, please complete the form below.

We value your investment and offer free customization with every report to fulfil your exact research needs.

Yes, I have read the privacy policy

This website is secure and your personal details are safe.

Frequently Asked Questions (FAQs):

1. What are the major factors driving the growth of the global lung cancer genomic testing medicine market?

Ans: The major factors driving the growth of the global lung cancer genomic testing medicine market is the rising number of cancer patients leading to recent launches of novel lung cancer genomic testing as well as expanding research into lung cancer with an emphasis on pharmacogenomics and development of companion diagnostics.

2. What will be the market size of the global lung cancer genomic testing medicine market in 2028?

Ans: Global lung cancer genomic testing medicine market is expected to reach USD 4.27 billion by 2028.

3. Which segment accounted for the largest share in the global lung cancer genomic testing medicine market?

Ans: The services segment accounted for the largest share in the global lung cancer genomic testing medicine market.

4. Which region is the most dominant in global lung cancer genomic testing medicine market?

Ans: North America region has the largest share in global lung cancer genomic testing medicine market.

5. Who are the key players in the global lung cancer genomic testing medicine market?

Ans: The key players in the global lung cancer genomic testing medicine market are QIAGEN, Agilent Technologies Inc., Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, CENTOGENE N.V., BGI, CeGaT GmbH, Illumina Inc., F. Hoffmann-La Roche Ltd, and other prominent players.

PLACE AN ORDER

SINGLE USER LICENSE
$ 3337.5 ~~$ 4450~~
GROUP LICENSE
$ 4162.5 ~~$ 5550~~
ENTERPRISE LICENSE
$ 5887.5 ~~$ 7850~~

ENQUIRE BEFORE PURCHASE

RELATED REPORTS

WHY CHOOSE US

24/7 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Coustom Research Service

Ask the Analyst to customize an exclusive study to serve your research needs
Quality & Accuracy

Ask the Analyst to customize an exclusive study to serve your research needs
Data Visualization

As the business world is changing dynamically every day. We need to stay pin point in relation to data management and optimum data utilization
Information security

We never share your personal and confidential information. Your personal information is safe and secure with us.

Lung Cancer Genomic Testing Medicine Market

Report Overview

Market Segmentation

To request a free sample copy of this report, please complete the form below.

Frequently Asked Questions (FAQs):

1. What are the major factors driving the growth of the global lung cancer genomic testing medicine market?

2. What will be the market size of the global lung cancer genomic testing medicine market in 2028?

3. Which segment accounted for the largest share in the global lung cancer genomic testing medicine market?

4. Which region is the most dominant in global lung cancer genomic testing medicine market?

5. Who are the key players in the global lung cancer genomic testing medicine market?

PLACE AN ORDER

RELATED REPORTS

WHY CHOOSE US

24/7 Research support

Coustom Research Service

Quality & Accuracy

Data Visualization

Information security